Organization
Bristol Myers Squibb, Global Drug Development, Princeton, United States of America
2 abstracts
Abstract
A NOVEL METHOD FOR PREDICTING 1-YEAR RETENTION OF ABATACEPT USING MACHINE LEARNING TECHNIQUES: DIRECTIONALITY AND IMPORTANCE OF PREDICTORSOrg: Schlosspark-Klinik University, Department of Internal Medicine, Rheumatology, Berlin, Germany, Tulsy, Co-founder, Paris, France, Excelya, N/A, Boulogne-Billancourt, France, Data Revenue GmbH, Machine Learning Engineering Department, Berlin, Germany, Private Practice, N/A, Brunoy, France,
Abstract
ACPA POSITIVITY DETERMINES REMISSION IN PATIENTS WITH RA TREATED WITH IV AND SC ABATACEPT: A POST HOC ANALYSIS OF THE REAL-WORLD OBSERVATIONAL ACTION AND ASCORE STUDIESOrg: Schlosspark-Klinik, University Medicine Berlin, Department of Internal Medicine, Rheumatology, Berlin, Germany, Bristol Myers Squibb, Medical Immunology & Fibrosis, Munich, Germany, Bristol Myers Squibb, MESP France – Market Access, Rueil-Malmaison, France, ARC Amsterdam University Hospitals – VU University Medical & Reade, Department of Rheumatology, Amsterdam, Netherlands, Bristol Myers Squibb, Global Drug Development, Princeton, United States of America,